2700 -- Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act | Poliscope

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

2700

116th Congress

Health

In Committee

Legislative Progress

✓

Introduced

Committee

Floor Vote

Other Chamber

Enacted

Introduced

May 14, 2019

Latest Action

June 26, 2019

Primary Sponsor

Michael C. BurgessRepublican(TX)

Momentum (last 30 days)

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

84pct

43d open

vs 9,062 other HR bills in the 116th — cohort avg 39d

Summary

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act This bill addresses prescription drugs and extends several health care, research, and workforce programs. Currently, a generic drug manufacturer is awarded 180 days of exclusivity on the market if it is the first applicant to file an application with the Food and Drug Administration (FDA), and the exclusivity period begins upon the first applicant's commercial marketing. The bill authorizes the FDAto approve a subsequent generic drug application prior to the first applicant's first date of commercial marketing if certain conditions are met. The bill prohibits a brand-name, generic, or biosimilar drug manufacturer from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exclusions, is a violation of the bill if the filer of the subsequent generic application receives something of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biological product. The developer of a drug or biological product, such as a generic or biosimilar version of a drug, may bring a civil action against the license holder of an approved drug if the holder has declined to make available sufficient quantities of the approved drug for the developer's testing. The bill also extends several health care, research, and workforce programs, including the National Health Service Corps, through FY2020.

Lobbying filings that explicitly cite this bill (34)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (7)

BRISTOL-MYERS SQUIBB COMPANY (10)GSK (FKA GLAXOSMITHKLINE INC.) (5)MASSACHUSETTS MEDICAL SOCIETY (2)NOVARTIS (3)PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (6)PLANNED PARENTHOOD ACTION FUND INC (2)PLANNED PARENTHOOD FEDERATION OF AMERICA, INC (2)

BRISTOL-MYERS SQUIBB COMPANYclient→BRISTOL-MYERS SQUIBB COMPANY

2020 · third_quarter · Health Issues

Committee	Chamber	Activity	Date
Judiciary Committee	House	Referred to	May 14, 2019
Energy and Commerce Committee	House	Referred to	May 14, 2019

Name	Party	State
Adam Kinzinger	Republican	IL
Ann Wagner	Republican	MO
Barry Loudermilk	Republican	GA

Bill	Congress	Relationship
S 340	116th	Related bill
S 192	116th	Related bill
HR 987	116th	Related bill

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

Summary

Lobbying filings that explicitly cite this bill (34)

Subjects (30)

Actions (5)

Committees

Text Versions

Cosponsors (44)

Related Bills (11)

Similar Bills (AI)